Anti-MUC1 aptamer: A potential opportunity for cancer treatment

被引：123

作者：

Nabavinia, Maryam Sadat ^{[1
]}

Gholoobi, Aida ^{[2
]}

Charbgoo, Fahimeh ^{[1
,3
]}

Nabavinia, Mahboobeh ^{[4
]}

Ramezani, Mohammad ^{[1
,5
]}

Abnous, Khalil ^{[3
,6
]}

机构：

[1] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Mashhad, Iran

[2] Mashhad Univ Med Sci, Sch Med, Dept Modern Sci & Technol, Mashhad, Iran

[3] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Iran

[4] Univ Illinois, Dept Bioengn, Chicago, IL USA

[5] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran

来源：

MEDICINAL RESEARCH REVIEWS | 2017年 / 37卷 / 06期

关键词：

antibody; aptamer; mucin 1 or MUC1; targeted therapy; EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; MONOCLONAL-ANTIBODY; TARGETED DELIVERY; CHITOSAN NANOPARTICLES; EMERGING CLASS; DNA APTAMERS; IN-VITRO; MUC1; THERAPY;

D O I：

10.1002/med.21462

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Mucin 1 (MUC1) is a protein usually found on the apical surface of most normal secretory epithelial cells. However, in most adenocarcinomas, MUC1 is overexpressed, so that it not only appears over the entire cell surface, but is also shed as MUC1 fragments into the blood stream. These phenomena pinpoint MUC1 as a potential target for the diagnosis and treatment of cancer; consequently, interest has increased in MUC1 as a molecular target for overcoming cancer therapy challenges. MUC1 currently ranks second among 75 antigen candidates for cancer vaccines, and different antibodies or aptamers against MUC1 protein are proving useful for tracing cancer cells in the emerging field of targeted delivery. The unique properties of MUC1 aptamers as novel targeting agents, and the revolutionary role that MUC1 now plays in cancer therapy, are the focus of this review. Recent advancements in MUC1-targeted cancer therapy are also assessed.

引用

页码：1518 / 1539

页数：22

共 86 条

[1] Photodynamic Therapy of Cancer: An Update [J].

Agostinis, Patrizia ;

Berg, Kristian ;

Cengel, Keith A. ;

Foster, Thomas H. ;

Girotti, Albert W. ;

Gollnick, Sandra O. ;

Hahn, Stephen M. ;

Hamblin, Michael R. ;

Juzeniene, Asta ;

Kessel, David ;

Korbelik, Mladen ;

Moan, Johan ;

Mroz, Pawel ;

Nowis, Dominika ;

Piette, Jacques ;

Wilson, Brian C. ;

Golab, Jakub .

CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) :250-281

[2] Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer [J].

Azhdarzadeh, Morteza ;

Atyabi, Fatemeh ;

Saei, Amir Ata ;

Varnamkhasti, Behrang Shiri ;

Omidi, Yadollah ;

Fateh, Mohsen ;

Ghavami, Mandi ;

Shanehsazzadeh, Saeed ;

Dinarvand, Rassoul .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2016, 143 :224-232

[3] MUC1 expression and its association with other aetiological factors and localization to mitochondria in preneoplastic and neoplastic gastric tissues [J].

Benjamin, J. B. Elisha ;

Jayanthi, Venkatraman ;

Devaraj, Halagowder .

CLINICA CHIMICA ACTA, 2010, 411 (23-24) :2067-2072

[4] Intracellular MUC1 Peptides Inhibit Cancer Progression [J].

Bitler, Benjamin G. ;

Menzl, Ina ;

Huerta, Carmen L. ;

Sands, Barbara ;

Knowlton, Wendy ;

Chang, Andrew ;

Schroeder, Joyce A. .

CLINICAL CANCER RESEARCH, 2009, 15 (01) :100-109

[5] Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to Anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer [J].

Borbas, K. Eszter ;

Ferreira, Catia S. M. ;

Perkins, Alan ;

Bruce, James I. ;

Missailidis, Sotiris .

BIOCONJUGATE CHEMISTRY, 2007, 18 (04) :1205-1212

[6] Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics [J].

Bruno, John G. .

MOLECULES, 2015, 20 (04) :6866-6887

[7] Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells [J].

Bruno, John Gordon .

IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2010, 46 (02) :107-113

[8] Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination [J].

Bulte, JWM ;

Zhang, SC ;

van Gelderen, P ;

Herynek, V ;

Jordan, EK ;

Duncan, ID ;

Frank, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15256-15261

[9] Emerging applications of multifunctional elastin-like recombinamers [J].

Carlos Rodriguez-Cabello, J. ;

Martin, Laura ;

Girotti, Alessandra ;

Garcia-Arevalo, Carmen ;

Javier Arias, F. ;

Alonso, Matilde .

NANOMEDICINE, 2011, 6 (01) :111-122

[10] Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients [J].

Carmon, Lior ;

Avivi, Irit ;

Kovjazin, Riva ;

Zuckerman, Tsila ;

Dray, Lillian ;

Gatt, Moshe E. ;

Or, Reuven ;

Shapira, Michael Y. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (01) :44-56

← 1 2 3 4 5 6 7 8 9 →